The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Open accessAbstract
OBJECTIVES: To provide updated estimates of Alzheimer disease (AD) dementia prevalence in the United States from 2010 through 2050. METHODS: Probabilities of AD dementia incidence were calculated from a longitudinal, population-based study including substantial numbers of both black and white participants. Incidence probabilities for single year of age, race, and level of education were calculated using weighted logistic regression and AD dementia diagnosis from 2,577 detailed clinical evaluations of 1,913 people obtained from stratified random samples of previously disease-free individuals in a population of 10,800. These were combined with US mortality, education, and new US Census Bureau estimates of current and future population to estimate current and future numbers of people with AD dementia in the United States. RESULTS: We estimated that in 2010, there were 4.7 million individuals aged 65 years or older with AD dementia (95% confidence interval [CI] = 4.0-5.5). Of these, 0.7 million (95% CI = 0.4-0.9) were between 65 and 74 years, 2.3 million were between 75 and 84 years (95% CI = 1.7-2.9), and 1.8 million were 85 years or older (95% CI = 1.4-2.2). The total number of people with AD dementia in 2050 is projected to be 13.8 million, with 7.0 million aged 85 years or older. CONCLUSION: The number of people in the United States with AD dementia will increase dramatically in the next 40 years unless preventive measures are developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As the U.S. population ages, the number of people with Alzheimer’s disease and related dementias (ADRD) is rapidly increasing,1,2”
From Review of Artificial Intelligence for Clinical Use in Alzheimer's Disease and Related Dementias (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sex is an important factor that contributes to the clinical and biological heterogeneities in Alzheimer’s disease (AD)”
From Sex-specific DNA methylation differences in Alzheimer’s disease pathology (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The aging of the baby-boom generation will significantly increase the number of people in the United States with Alzheimer's.70”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [70]
The cited source says what the claim attributes to it.
In the citing paper
“The aging of the population, including the baby‐boom generation, will significantly increase the number of people in the United States with Alzheimer's dementia.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [78]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Of all AD patients in the United States, around two-thirds are women [2].”
From Sex specific molecular networks and key drivers of Alzheimer’s disease (2023) · cites this paper as [2]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Almost two-thirds of AD patients in the U.S. are women [2]”
From Sex-specific DNA methylation differences in Alzheimer’s disease pathology (2021) · cites this paper as [2]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,385
Statistical Analysis with Missing Data
Little, R. J. A., & Rubin, D. B. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781119013563 · Cited by 8,473
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Self-citationPrevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932
Brookmeyer, R., Gray, S. G., & Kawas, C. H. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,802
2005 American Community Survey 1-Year Estimates
(2016) · Cited by 1,241
Missed and Delayed Diagnosis of Dementia in Primary Care: Prevalence and Contributing Factors
Bradford, A., Kunik, M. E., Schulz, P., Williams, S. P., & Singh, H. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181a6bebc · Cited by 969
Glover, J. W. (2010) · Cited by 917
Age-specific incidence rates of Alzheimer’s disease: The Baltimore Longitudinal Study of Aging
Kawas, C., Gray, S., Brookmeyer, R., Fozard, J., & Zonderman, A. (2000) · Neurology · doi:10.1212/wnl.54.11.2072 · Cited by 472
Research works printed but not linked: 1
- Bienias JL Kott PS Evans DA. Applying the delete-a-group jacknife varience estimator to analyses of data from a complex longitudinal survey . Proceedings of the Annual Meeting of the American Statistical Association Section on Survey Research Methods. Alexandria: American Statistical Association; 2003:539–544.
Cited by
Sorted by citations
Items 701–800 of 1,012
McCarron, H. R., Zmora, R., & Gaugler, J. E. (2019) · JMIR Aging · doi:10.2196/13378 · Cited by 41
Novel Alzheimer’s disease subtypes identified using a data and knowledge driven strategy
Mitelpunkt, A., Galili, T., Kozlovski, T., Bregman, N., Shachar, N., Marcus-Kalish, M., & Benjamini, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-57785-2 · Cited by 40
Managing Behavioral and Psychological Symptoms of Dementia
Gerlach, L. B., & Kales, H. C. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.11.010 · Cited by 45
Chen, Y., Li, Y., Fang, J.-Y., Li, P., & Li, F. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112834 · Cited by 42
Chen, M., Li, L., Liu, C., & Song, L. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03852-1 · Cited by 41
Do serum GDNF levels correlate with severity of Alzheimer’s disease?
Sharif, M. O., Noroozıan, M., & Hashemian, F. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04909-1 · Cited by 41
Guo, X., Yamashita, M., Suzuki, M., Ohsawa, C., Asano, K., Abe, N., Soshi, T., & Sekiyama, K. (2020) · Human Brain Mapping · doi:10.1002/hbm.25298 · Cited by 46
Raut, S., Patel, R., & Al-Ahmad, A. J. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00235-y · Cited by 42
Hua, A. Y., Wells, J. L., Brown, C. L., & LEVENSON, R. W. (2021) · Clinical Psychological Science · doi:10.1177/2167702620974368 · Cited by 50
Aitken, W. W., Lombard, J. L., Wang, K., Toro, M., Byrne, M. M., Nardi, M. I., Kardys, J., Parrish, A. K., Dong, C., Szapocznik, J., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201179 · Cited by 41
“As of 2020, it is estimated that there are 5.8 million adults aged 65 years or older living with AD in the United States, or approximately one in ten people aged 65 years or older [1, 2].”
InfluentialKaranth, S. D., Katsumata, Y., Nelson, P. T., Fardo, D. W., McDowell, J. K., Schmitt, F. A., Kryscio, R. J., Browning, S. R., Braithwaite, D., Arnold, S. M., et al. (2022) · Brain · doi:10.1093/brain/awac035 · Cited by 38
Applications of induced pluripotent stem cells in studying the neurodegenerative diseases
Wan, W., Cao, L., Kalionis, B., Xia, S., & Tai, X. (2015) · Stem Cells International · doi:10.1155/2015/382530 · Cited by 40
Time to dementia diagnosis by race: A retrospective cohort study
Davis, M. A., Lee, K. A., Harris, M., Ha, J., Langa, K. M., Bynum, J., & Hoffman, G. J. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18078 · Cited by 40
“Due to an increase in population age and longevity, the number of Americans with Alzheimer's disease and related dementias (ADRD) is expected to increase from the current estimate of 5 million to over 13 million by 2050.(1) A major goal of the National Plan to Address Alzheimer's Disease is to enhance care quality and…”
BackgroundZhang, Y., Ebelt, S., Shi, L., Scovronick, N., D’Souza, R. R., Steenland, K., & Chang, H. H. (2022) · SSRN Electronic Journal · doi:10.1016/j.envres.2022.115176 · Cited by 42
2026 Alzheimer's disease facts and figures
(2026) · Alzheimer s & Dementia · doi:10.1002/alz.71345 · Cited by 69
Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer’s Disease
McClam, T. D., Marano, C. M., Rosenberg, P. B., & Lyketsos, C. G. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000097 · Cited by 45
Kannaian, B., Sharma, B., Phillips, M. F., Chowdhury, A., Manimekalai, M. S. S., Adav, S. S., Ng, J. T. Y., Kumar, A., Lim, S., Mu, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48819-5 · Cited by 41
Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults
McSweeney, M., Binette, A. P., Meyer, P., Gonneaud, J., Bedetti, C., Ozlen, H., Labonté, A., Rosa‐Neto, P., Breitner, J. C. S., Poirier, J., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000008905 · Cited by 41
Crosstalk Between the Gut Microbiome and Bioactive Lipids: Therapeutic Targets in Cognitive Frailty
Baptista, L. C. P., Sun, Y., Carter, C. S., & Buford, T. W. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.00017 · Cited by 46
Deep Brain Stimulation for Alzheimer’s Disease: Tackling Circuit Dysfunction
Lam, J., Lee, J., Liu, C. Y., Lozano, A. M., & Lee, D. J. (2020) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.13305 · Cited by 44
Lind, K. E., Hildreth, K. L., Lindrooth, R. C., Morrato, E. H., Crane, L. A., & Perraillon, M. C. (2021) · Health Services Research · doi:10.1111/1475-6773.13627 · Cited by 39
Walton, C. C., Kavanagh, A., Downey, L. A., Lomas, J. E., Camfield, D., & Stough, C. K. K. (2014) · Translational Neuroscience · doi:10.1515/tnsci-2015-0003 · Cited by 40
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
Schadt, E. E., Buchanan, S., Brennand, K. J., & Merchant, K. M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00252 · Cited by 39
Reed, R. G., Carroll, J., Marsland, A. L., & Manuck, S. B. (2022) · Aging · doi:10.18632/aging.204376 · Cited by 39
Tseng, P., Zeng, B., Suen, M., Wu, Y., Correll, C. U., Zeng, B., Kuo, J. S., Chen, Y.-W., Chen, T., Tu, Y.-K., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.04.017 · Cited by 39
Waiker, D. K., Verma, A., Akhilesh, A., Gajendra, T. A., Singh, N., Roy, A., Dilnashin, H., Tiwari, V., Trigun, S. K., Singh, S. P., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00245 · Cited by 40
Liu, N., Liang, X., Chen, Y., & Xie, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102199 · Cited by 44
Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology
Dhariwal, R., Jain, M., Mir, Y. R., Singh, A., Jain, B., Kumar, P., Tariq, M., Verma, D., Deshmukh, K., Yadav, V. K., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1522223 · Cited by 47
“Neuro-disorders with marked allelic and locus heterogeneity often show individually large, rare, and even private conditions (53).”
An, L., Adeli, E., Liu, M., Zhang, J., Lee, S., & Shen, D. G. (2017) · Scientific Reports · doi:10.1038/srep45269 · Cited by 40
Medication Profiles of Patients with Cognitive Impairment and High Anticholinergic Burden
Green, A. R., Reifler, L. M., Boyd, C. M., Weffald, L. A., & Bayliss, E. A. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0522-x · Cited by 40
Efficacy of Cognitive Rehabilitation in Alzheimer Disease: A 1-Year Follow-Up Study
Germain, S., Wojtasik, V., Lekeu, F., Quittre, A., Olivier, C., Godichard, V., & Salmon, É. (2018) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988718813724 · Cited by 39
Chen, J., Huang, W., Cheng, C., Zhou, L., Jiang, G.-B., & Hu, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00290 · Cited by 39
Imaging Mass Spectrometry: A New Tool to Assess Molecular Underpinnings of Neurodegeneration
Chen, K., Baluya, D. L., Tosun, M., Li, F., & Maletić‐Savatić, M. (2019) · Metabolites · doi:10.3390/metabo9070135 · Cited by 41
Knox, S., Downer, B. G., Haas, A. M., Middleton, A., & Ottenbacher, K. J. (2019) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.09.012 · Cited by 41
Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer’s Disease
Lim, W. L. F., Huynh, K., Chatterjee, P., Martins, I. J., Jayawardana, K. S., Giles, C., Mellett, N. A., Laws, S. M., Bush, A. I., Rowe, C. C., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191304 · Cited by 37
Implementing and sustaining family care programs in real-world settings: Barriers and facilitators
Hodgson, N. A., & Gitlin, L. N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-813898-4.00006-3 · Cited by 39
Kim, Y., Pérez‐González, R., Miller, C., Kurz, M., D’Acunzo, P., Goulbourne, C. N., & Levy, E. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03701-1 · Cited by 42
“Given that sex, in addition to aging, is an established risk factor for AD, where females have higher incidence compared to males [21, 22], the age-associated increase in secretion of brain microvesicles and exosomes into the extracellular space only in females suggest that EVs contribute to AD…”
Kim, J. S., Han, J. W., Bae, J. B., Moon, D. G., Shin, J. Y., Kong, J. E., Lee, H., Yang, H. W., Lim, E., Kim, J. Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-22917-3 · Cited by 40
Huang, G., Li, R., Bai, Q., & Alty, J. (2023) · Health Information Science and Systems · doi:10.1007/s13755-023-00231-0 · Cited by 40
“There are considerably higher rates of these disorders in older adults; for example, in the population of adults aged 60–70 about 1 in 10 have AD [1], and 1 in 100 have PD [2]; in the population of adults aged over 85, these figures are almost 1 in 3, and 4 in 100, for AD and PD respectively.”
BackgroundSchindler, S. E., & Fagan, A. M. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00142 · Cited by 40
Granger, M. W., Franko, B., Taylor, M. W., Messier, C., George‐Hyslop, P. S., & Bennett, S. A. L. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150587 · Cited by 41
Arpawong, T. E., Pendleton, N., Mekli, K., McArdle, J. J., Gatz, M., Armoskus, C., Knowles, J. A., & Prescott, C. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182448 · Cited by 38
Current Therapeutic Targets for Alzheimer's Disease
Chaudhary, A., Maurya, P. K., Yadav, B. S., Singh, S., & Mani, A. (2018) · Journal of Biomedicine · doi:10.7150/jbm.26783 · Cited by 39
Computational Methods for the Discovery of Metabolic Markers of Complex Traits
Lee, M. Y., & Hu, T. (2019) · Metabolites · doi:10.3390/metabo9040066 · Cited by 39
Honarpisheh, P., & McCullough, L. D. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14675 · Cited by 41
Chai, S. C., Jerusik, J., Davis, K., Wright, R. S., & Zhang, Z. (2019) · Food & Function · doi:10.1039/c9fo00913b · Cited by 39
Rubin, S. S., Manevich, A., & Doron, I. I. (2019) · Death Studies · doi:10.1080/07481187.2019.1688014 · Cited by 38
Redox-Dependent Copper Ion Modulation of Amyloid-β (1-42) Aggregation In Vitro
Sasanian, N., Bernson, D., Horváth, I., Wittung-Stafshede, P. E., & Esbjörner, E. K. (2020) · Biomolecules · doi:10.3390/biom10060924 · Cited by 38
“AD is the most common form of adult dementia, mainly afflicting people over the age of 65 [2].”
BackgroundFrom Small Molecules to Synthesized Polymers: Potential Role in Combating Amyloidogenic Disorders
Ghosh, P., Bera, A., Bhadury, P., & De, P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00104 · Cited by 38
Insulin Resistance as a Common Link Between Current Alzheimer’s Disease Hypotheses
Alves, S. S., da Silva-Júnior, R. M. P., Servilha‐Menezes, G., Homolak, J., Šalković‐Petrišić, M., & Garcia‐Cairasco, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210234 · Cited by 39
“IntheUnitedStates,itisesti-matedthatonein10peopleage65andolderhaveAD, a total number of 5.8 million Americans [9, 10].”
InfluentialAutophagy Balances Neuroinflammation in Alzheimer’s Disease
Cheng, X., Wei, Y. Q., Qian, Z., & Han, L. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01269-6 · Cited by 40
Noel, M. A., Kaluzynski, T. S., & Templeton, V. H. (2015) · Journal of Applied Gerontology · doi:10.1177/0733464815589986 · Cited by 38
Walling, A. M., Pevnick, J. M., Bennett, A. V., Vydiswaran, V. G. V., & Ritchie, C. S. (2023) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocad086 · Cited by 38
Mitochondrial transplantation rescues neuronal cells from ferroptosis
Chen, T., Majerníková, N., Marmolejo-Garza, A., Trombetta-Lima, M., Sabogal-Guáqueta, A. M., Zhang, Y., ten Kate, R., Zuidema, M., Mulder, P. P. M. F. A., den Dunnen, W. F. A., et al. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.07.034 · Cited by 37
Kounnas, M. Z., Lane‐Donovan, C., Nowakowski, D. W., Herz, J., & Comer, W. T. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.09.003 · Cited by 37
Luteinizing hormone acts at the hippocampus to dampen spatial memory
Burnham, V. L., Sundby, C. S., Laman-Maharg, A., & Thornton, J. E. (2016) · Hormones and Behavior · doi:10.1016/j.yhbeh.2016.11.007 · Cited by 36
Clinical Studies of Social Neuroscience: A Lesion Model Approach
Kumfor, F., Hazelton, J. L., Winter, F. D., de Langavant, L. C., & den Stock, J. V. (2017) · Springer eBooks · doi:10.1007/978-3-319-68421-5_12 · Cited by 36
How Does Psychosocial Behavior Contribute to Cognitive Health in Old Age?
Wilson, R., & Bennett, D. A. (2017) · Brain Sciences · doi:10.3390/brainsci7060056 · Cited by 39
Vitamin E and Alzheimer’s Disease—Is It Time for Personalized Medicine?
Cervantes, B. R., & Ulatowski, L. M. (2017) · Antioxidants · doi:10.3390/antiox6030045 · Cited by 37
Increased Serum Acylated Ghrelin Levels in Patients with Mild Cognitive Impairment
Cao, X., Zhu, M., He, Y., Chu, W., Du, Y., & Du, H. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170721 · Cited by 39
Wireless Optogenetic Nanonetworks for Brain Stimulation: Device Model and Charging Protocols
Wirdatmadja, S., Barros, M. T., Koucheryavy, Y. A., Jornet, J. M., & Balasubramaniam, S. (2017) · IEEE Transactions on NanoBioscience · doi:10.1109/tnb.2017.2781150 · Cited by 37
van der Hoek, M. D., Nieuwenhuizen, A. G., Keijer, J., & Ashford, J. W. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181003 · Cited by 37
Al-Atrache, Z., Lopez, D. B., Hingley, S. T., & Appelt, D. M. (2019) · BMC Neuroscience · doi:10.1186/s12868-019-0489-5 · Cited by 37
Thirunavu, V. M., McCullough, A. A., Su, Y., Flores, S. E., Dincer, A., Morris, J. C., Cruchaga, C., Benzinger, T. L. S., & Gordon, B. A. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190154 · Cited by 37
Home-Based, Adaptive Cognitive Training for Cognitively Normal Older adults: Initial Efficacy Trial
Lee, H., Kent, J. D., Wendel, C. S., Wolinsky, F. D., Foster, E. D., Merzenich, M. M., & Voss, M. W. (2019) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbz073 · Cited by 35
Imperatore, J. A., Then, M. L., McDougal, K. B., & Mihailescu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030767 · Cited by 37
Biomarkers: Our Path Towards a Cure for Alzheimer Disease
Tarawneh, R. M. (2020) · Biomarker Insights · doi:10.1177/1177271920976367 · Cited by 42
Yan, Y., Wu, X., Wang, X., Geng, Z., Wang, L., Xiao, G., Wu, Y., Zhou, S., Liao, R., Wei, L., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200971 · Cited by 37
“AD prevalence has been projected to triple by 2050 given the increas-ISSN ingly aging population [2].”
Interactive rather than independent effect of APOE and sex potentiates tau deposition in women
Wang, Y., Pascoal, T. A., Therriault, J., Kang, M. S., Benedet, A. L., Savard, M., Tissot, C., Lussier, F. Z., Arias, J. F., Mathotaarachchi, S. S., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab126 · Cited by 37
Yamashita, K., Watanabe, S., Ishiki, K., Miura, M., Irino, Y., Kubo, T., Matsui, J., Hagino, K., Iwanaga, S., & Yoshida, T. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.066 · Cited by 37
Downer, B. G., García, M. A., Saenz, J. L., Markides, K. S., & Wong, R. (2017) · Research on Aging · doi:10.1177/0164027517701447 · Cited by 37
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36
Ba, D. M., Gao, X., Al‐Shaar, L., Muscat, J. E., Chinchilli, V. M., Ssentongo, P., Beelman, R. B., & Richie, J. P. (2022) · British Journal Of Nutrition · doi:10.1017/s0007114521005195 · Cited by 36
“It is projected the total number of people with Alzheimer’s disease dementia in the US will reach 13·8 million in 2050 unless preventive measures are developed(7).”
BackgroundMaurer, L. L., & Philbert, M. A. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfu254 · Cited by 36
Lon, H., Mendonça, N., Goss, S. L., Othman, M. I. A., Locke, C. S., Jin, Z., & Rendenbach‐Mueller, B. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.598 · Cited by 36
Yu, F., Lin, F. V., Salisbury, D. L., Shah, K. N., Chow, L. S., Vock, D. M., Nelson, N. W., Porsteinsson, A. P., & Jack, C. R. (2018) · Trials · doi:10.1186/s13063-018-3054-0 · Cited by 38
Goukasian, N., Porat, S., Blanken, A. E., Avila, D., Zlatev, D. V., Hurtz, S., Hwang, K., Pierce, J., Joshi, S. H., Woo, E., et al. (2019) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000490044 · Cited by 36
Denver, P., D’Adamo, H., Hu, S., Zuo, X., Zhu, C., Okuma, C., Kim, P., Castro, D., Jones, M. R., Leal, C. D. R., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01269 · Cited by 37
Companion animal models of neurological disease
Partridge, B. R., & Rossmeisl, J. H. (2019) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2019.108484 · Cited by 36
Divergence in the metabolome between natural aging and Alzheimer’s disease
Hunsberger, H. C., Greenwood, B. P., Tolstikov, V., Narain, N. R., Kiebish, M. A., & Denny, C. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-68739-z · Cited by 37
Modulated delivery of donepezil using a combination of skin microporation and iontophoresis
Kale, M. S., Kipping, T., & Banga, A. K. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119853 · Cited by 36
Faieta, J. M., Sheehan, J., & DiGiovine, C. P. (2020) · Assistive Technology · doi:10.1080/10400435.2020.1829174 · Cited by 36
“), is anticipated to affect more than 13 million in America alone by 2050 (Hebert et al., 2013).”
BackgroundD. Bruce, K., Tang, M., Reigan, P., & H. Eckel, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218338 · Cited by 36
“While its precise function remains elusive, we have previously shown LPL is a feature of phagocytic and ‘reparative’ microglia and is involved in microglial lipid and lipoprotein uptake [1].”
BackgroundInfluentialThe INESC-ID Multi-Modal System for the ADReSS 2020 Challenge
Pompili, A., Rolland, T., & Abad, A. (2020) · Interspeech (USB) · doi:10.21437/interspeech.2020-2833 · Cited by 39
“census reported that 3% of people aged 65-74, 17% of people aged 75-84, and 32% of people aged 85 and older have AD [2].”
BackgroundCerebellar network organization across the human menstrual cycle
Fitzgerald, M., Pritschet, L., Santander, T., Grafton, S. T., & Jacobs, E. G. (2020) · Scientific Reports · doi:10.1038/s41598-020-77779-4 · Cited by 37
Kim, J., & Kim, Y. (2021) · Biomedicines · doi:10.3390/biomedicines9010082 · Cited by 36
“One in every 2–3 people over the age of 85 will develop AD-related dementia [3], and most AD patients experience mild cognitive impairment (MCI), which is the preclinical status of dementia with modest cognitive decline without dysfunction in daily life [4,5].”
BackgroundChen, H., Petty, L. E., Sha, J., Zhao, Y., Kuzma, A. B., Valladares, O., Bush, W. S., Naj, A. C., Gamazon, E. R., & Below, J. E. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01677-0 · Cited by 36
“INTRODUCTION Late-onset Alzheimer’s disease (LOAD) is the most common neurodegenerative disease in the world, occurring in >35% of individuals age 85 years and older [1], and it is the sixth most common cause of death in the US.”
BackgroundKhan, K. M., Balasubramanian, N., Gaudencio, G., Wang, R., Selvakumar, G. P., Kolling, L. J., Pierson, S. R., Tadinada, S. M., Abel, T. G., Hefti, M. M., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01546-5 · Cited by 37
Cellular senescence and neurodegeneration
Holloway, K., Neherin, K., Dam, K. U., & Zhang, H. (2023) · Human Genetics · doi:10.1007/s00439-023-02565-x · Cited by 40
Seminara, R. S., Jeet, C., Biswas, S., Kanwal, B., Iftikhar, W., Sakibuzzaman, M., & Rutkofsky, I. H. (2018) · Cureus · doi:10.7759/cureus.3285 · Cited by 36
Longitudinal assessment of physical activity and cognitive outcomes among women at midlife
Greendale, G. A., Han, W., Huang, M., Upchurch, D. M., Karvonen-Gutierrez, C., Avis, N. E., & Karlamangla, A. S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.3227 · Cited by 37
Saeedi, M., & Mehranfar, F. (2022) · Recent Patents on Biotechnology · doi:10.2174/1872208316666220302115901 · Cited by 36
Immunosenescence as a convergence pathway in neurodegeneration
Mohapatra, L., Mishra, D. K., Tripathi, A. S., & Parida, S. K. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110521 · Cited by 38
Impact of hippocampal neuronal ablation on neurogenesis and cognition in the aged brain
Yeung, S. T., Myczek, K., Kang, A., Chabrier, M. A., Baglietto‐Vargas, D., & LaFerla, F. M. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.11.054 · Cited by 35
Stuck in the mud: time for change in the implementation of cognitive training research in ageing?
Walton, C. C., Mowszowski, L., Lewis, S. J. G., & Naismith, S. L. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00043 · Cited by 41
The ONDRISeq panel: custom-designed next-generation sequencing of genes related to neurodegeneration
Farhan, S. M. K., Dilliott, A. A., Ghani, M., Sato, C., Liang, E., Zhang, M., McIntyre, A. D., Cao, H., Racacho, L., Robinson, J. F., et al. (2016) · npj Genomic Medicine · doi:10.1038/npjgenmed.2016.32 · Cited by 34
Exploring Selection Bias by Causal Frailty Models
Stensrud, M. J., Valberg, M., Røysland, K., & Aalen, O. O. (2017) · Epidemiology · doi:10.1097/ede.0000000000000621 · Cited by 35
Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease
Lee, S. A. W., Sposato, L. A., Hachinski, V., & Cipriano, L. E. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0243-0 · Cited by 38
Assessing the binding of cholinesterase inhibitors by docking and molecular dynamics studies
Ali, M. R., Sadoqi, M., Møller, S. G., Boutajangout, A., & Mezei, M. (2017) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2017.06.027 · Cited by 34
The blood brain barrier: Insights from development and ageing
Delaney, C. P., & Campbell, M. (2017) · Tissue Barriers · doi:10.1080/21688370.2017.1373897 · Cited by 36
Metadata
- Authors
- Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A.
- Affiliations
- Rush University (US)
- Venue
- Neurology
- Published
- 2013-05-07
- Volume
- 80
- Issue
- 19
- Pages
- 1778-1783
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC3719424
- OpenAlex
- W2071068165
- Cited by
- 2,642
- References
- 19
- Citations by year
- 2026: 81 · 2025: 119 · 2024: 192 · 2023: 167 · 2022: 242 · 2021: 312 · 2020: 317 · 2019: 232 · 2018: 210 · 2017: 212 · 2016: 217 · 2015: 160 · 2014: 129 · 2013: 47
- FWCI
- 131.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- National Institutes of Health (AG011101)
- National Institute on Aging (RC2AG036650, U01AG012505, R01AG030146, AG011101, R01AG011101, P30AG010161, R01AG021972, R01AG009966)
- National Heart, Lung, and Blood Institute (R01HL084209)
- National Institute of Nursing Research (R01NR009543, R01NR010211)
- National Institute of Environmental Health Sciences (R21ES020404, R01ES010902, R21ES019712)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Social Sciences › Demography › Insurance, Mortality, Demography, Risk Management
- Keywords
- Alzheimer's disease, dementia prevalence, population projections, older adults, age-specific prevalence, racial differences, educational attainment, population aging, United States
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Forecasting, Humans, Longitudinal Studies, Male, Population Surveillance, United States, Incidence, Censuses
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
